Victoria Socha

DocwireNews

An estimated 6.5 million adults in 
the United States are affected by heart failure and the prevalence is expected 
to increase by nearly 50% from 2012 to 2030. The lifetime risk for heart 
failure is estimated at 20% to 45%. Increasingly, ventricular assist devices 
(VADs) are used for treatment of patients with advanced heart failure that is 
not managed with more conservative therapies. Outcomes in patients with VADs 
and reduced kidney function are poor both pre- and postoperatively. Estimates 
of the incidence and outcomes of acute kidney injury (AKI) in the setting of 
VAD placement are hampered by the wide variation in the definition of AKI.In conjunction with an increase in 
the use of VADs, containment of healthcare costs becomes an issue. Among patients 
covered by Medicare who received VADs from 2006 to 2011, the mean Medicare 
payment for the VAD implantation hospitalization was $210,000; the costs 
remained stable during that 5-year period.Carl P. Walther, MD, MS, and colleagues conducted a cohort 
study to compare outcomes by the absence versus presence of diagnosed AKI and 
AKI requiring dialysis (AKI-D) during hospitalizations with implantable VAS 
placement in the United States. The researchers sought to examine whether 
recent trends in relevant outcomes differed in the two AKI categories. Results 
of the study were reported in the American Journal of Kidney Diseases 
[2019;74(5):650-658].The study extracted data from the 
National Inpatient Sample (NIS) database from January 1, 2006, to December 31, 
2015. The NIS, a 20% stratified sample of discharges from US community 
hospitals, includes data on all payers of inpatient healthcare in the United 
States from more than 7 million hospital stays annually.Patients &ge;18 years of age who 
received an implanted VAD and had a diagnosis code indicating heart failure 
and/or shock or had a separately coded cardiac surgery during the 
hospitalization were included in the study. In 2005, the International 
Classification of Diseases, Ninth Revision, Clinical Modification, refined 
procedure codes to distinguish implantable VADs from nonimplantable VADs. Exclusion 
criteria were codes for end-stage renal disease (ESRD) but none for AKI, and 
receiving dialysis but not having codes for either AKI or ESRD. Individuals 
with codes for AKI and ESRD were included.The primary outcome of interest was 
in-hospital mortality; length of stay was also evaluated.Hospital costs were estimated using 
total hospital charges, reported for each discharge in the NIS, multiplied by 
the applicable cost-to-charge ratios. The Consumer Price Index for Hospital and 
Related Services was used to adjust costs to reflect changes in 
hospital-related costs, indexed to 2015.During the study period, there were 
an estimated 24,140 hospitalizations with VAD implantation. The number 
increased from 853 in 2006 to 3945 in 2015.Of the 24,140 hospitalizations with 
VAD implantation, AKI was among the first 15 discharge codes in 56.1%: 49.6% 
had a code for AKI but no dialysis procedure and 6.5% had AKI and dialysis 
procedure coded. There was an increase from 2006 to 2015 in the proportion of 
hospitalizations with coded AKI, both with and without dialysis, from 44.0% in 
2006 to 2007 to 61.7% in 2014 to 2015. During the same period, the proportions 
of hospitalizations with AKI-D declined from 9.3% to 5.2%. The proportion of 
AKI would increase from 56.1% to 57.8% if AKI diagnosis ascertainment were 
extended to all codes in each record.Overall, in-hospital mortality was 
14.5% (95% confidence interval [CI], 13.3%-15.8%). During the study period, 
mortality declined from 36.7% (95% CI, 29.7%-43.7%) in 2006 to 2007 to 10.2% 
(95% CI, 8.7%-11.7%) in 2014 to 2015. In patients without a diagnosis of AKI 
and among those with an AKI diagnosis without dialysis, there was a marked 
decline in unadjusted in-hospital mortality during the study period; the 
decline was more prominent in the earlier years. Among those with AKI-D, the 
decline in mortality was much less pronounced.The median length of stay was 29 
days. Among the patients who survived the index hospitalization, patients with 
AKI-D had the longest length of stay (48 days) compared with those without AKI 
(25 days) or those with AKI not requiring dialysis (33 days).In 2006 to 2007, mean hospitalization 
cost (in 2015 terms) was $319,096 (95% CI, $288,145-$350,047); costs decreased 
to $245,943 (95% CI, $234,697-$257,191) in 2014 to 2015. Among patients without 
AKI, mean hospitalization costs were $232,492 (95% CI, $223,905-$241,078), 
compared with $288,448 (95% CI, $278,321-$298,575) among patients with AKI not 
requiring dialysis and $365,080 (95% CI, $337,662-$392,497) among patients with 
AKI-D.Compared with hospitalizations 
without AKI, costs were 19.1% (95% CI, 15.4%-22.9%) higher in patients with AKI 
without dialysis and 39.6% (95% CI, 30.6%-49.3%) higher in patients with AKI-D, 
following adjustment for demographics, comorbid conditions, and hospitalization 
circumstance.At discharge, 19.6% of patients 
without AKI were transferred to another facility (another acute-care hospital, 
skilled nursing facility, or rehabilitation facility). Among patients with AKI 
not requiring dialysis, the proportion was 31.5%; among those with AKI-D, the 
proportion was 47.7%.The inability to determine the timing 
of AKI with respect to VAD implantation was cited by the authors as a 
limitation to the study. Also cited were limitations in determining the 
prevalence of pre-existing chronic kidney disease and discharge weights could not 
be determined for a subpopulation of interest.&ldquo;In conclusion, as VADs are 
increasingly used in the management of end-stage heart failure refractory to 
medical management, understanding and ameliorating pre- and postoperative 
decreases in kidney function is necessary. Diagnosis of AKI has increased 
during the study period, likely due to more appreciation of the importance of 
AKI and increasing sensitivity of AKI definition, but dialysis-requiring AKI 
has decreased. Mortality risk among VAD recipients with AKI not requiring 
dialysis is improving, but among persons with AKI-D, excess mortality remains 
high. This study highlights the need for further investigations into 
understanding and reducing the severity of AKI related to end-stage heart 
failure and VAD implantation,&rdquo; the researchers said.Takeaway Points<ol class="wp-block-list">
<li>Patients undergoing implantation of 
ventricular assist devices (VADs) to manage end-stage heart failure are at risk 
for acute kidney injury (AKI) that may or may not require dialysis.</li>
<li>Of patients who underwent implantation 
of a VAD from 2006 to 2015, 56.1% developed AKI; of those, 6.5% required 
dialysis (AKI-D). AKI diagnosis increased during the study period; the 
prevalence of AKI-D declined. Mortality declined in all AKI categories; the 
smallest decline was among patients with AKI-D. </li>
<li>Compared with patients with no AKI, 
adjusted hospitalization costs were 19.1% higher in patients with AKI and 39.6% 
higher among patients with AKI-D.</li>
</ol>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

AKI with VAD Placement Increased from 2006 to 2015

Acute Kidney Injury

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe